This trial is testing a CMV vaccine in children undergoing stem cell transplants to see if it is safe and effective.
5 Primary · 16 Secondary · Reporting Duration: Up to 1 year, rising CMV viremia or viremia >= 3,705
Experimental Treatment
80 Total Participants · 1 Treatment Group
Primary Treatment: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine · No Placebo Group · Phase 1 & 2
Age 1 - 21 · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: